- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05756153
A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation
March 7, 2024 updated by: Zhejiang Genfleet Therapeutics Co., Ltd.
A Phase Ib/II, Multi-Center, Open-Label Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation
This is a Phase Ib/II study.
The objectives are to evaluate the safety/tolerability and efficacy of GFH925 in combination with Cetuximab in advanced KRAS G12C mutant NSCLC, to characterize pharmacokinetics (PK) of GFH925 in combination with Cetuximab in advanced KRAS G12C mutant NSCLC
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
45
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Therapeutics Genfleet
- Phone Number: +86 21 6882 1388
- Email: GFH925X0201@genfleet.com
Study Locations
-
-
Haidari
-
Athens, Haidari, Greece, 12462
- Recruiting
- University General Hospital "Attikon"
-
Contact:
- Anna Koumarianou
-
-
-
-
Emilia-Romagna
-
Bologna, Emilia-Romagna, Italy, 40138
- Recruiting
- Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS
-
Contact:
- Stefania Salvagni
-
-
Friuli-Venezia Giulia
-
Aviano, Friuli-Venezia Giulia, Italy, 33081
- Recruiting
- IRCCS Centro di Riferimento Oncologico
-
Contact:
- Elisa De Carlo
-
Padova, Friuli-Venezia Giulia, Italy, 35218
- Recruiting
- IOV - Istituto Oncologico Veneto IRCCS
-
Contact:
- Valentina Guarneri
-
-
Lazio
-
Roma, Lazio, Italy, 00144
- Recruiting
- Istituto Nazionale Tumori Regina Elena IRCCS
-
Contact:
- Federico Cappuzzo
-
-
Lombardia
-
Milano, Lombardia, Italy, 20133
- Recruiting
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Contact:
- Giuseppe Lo Russo
-
-
Piemonte
-
Candiolo, Piemonte, Italy, 10060
- Recruiting
- Candiolo Cancer Institute, FPO-IRCCS
-
Contact:
- Vanesa Gregorc
-
-
Toscana
-
Siena, Toscana, Italy, 53100
- Recruiting
- A.O.U. Senese Policlinico Santa Maria alle Scotte
-
Contact:
- Michele Maio
-
-
Veneto
-
Verona, Veneto, Italy, 37126
- Recruiting
- Azienda Ospedaliera Universitaria Integrata Verona (Ospedale Borgo Roma)
-
Contact:
- Michele Milella
-
-
-
-
-
Barcelona, Spain, 8035
- Recruiting
- Hospital Universitari Vall d'Hebron
-
Contact:
- Enriqueta Felip Font
-
Barcelona, Spain, 8017
- Recruiting
- Clínica Mi Tres Torres
-
Contact:
- Viteri Santiago
- Phone Number: 0034 932287445
- Email: sviteri@uomi.es
-
Barcelona, Spain, 08028
- Recruiting
- Hospital Universitari Dexeus,Servicio de Oncologia Medica
-
Contact:
- Maria Gonzalez Cao
-
Barcelona, Spain, 08041
- Recruiting
- ICO Badalona - Hospital Universitari Germans Trias i Pujol,Servicio de Oncologia Medica
-
Contact:
- Margarita Majem Tarruella
-
Málaga, Spain, 29010
- Recruiting
- Hospital Regional Universitario de Malaga,Oncology Dept
-
Contact:
- Maria Vanesa Gutierrez Calderon
-
Sevilla, Spain, 41013
- Recruiting
- Virgen del Rocio University Hospital
-
Contact:
- Reyes Bernabe Caro
-
Valencia, Spain, 46009
- Recruiting
- Instituto Valenciano de Oncologia IVO,Servicio de Oncologia Medica
-
Contact:
- Ignacio Gil Bazo
-
-
Barcelona
-
Badalona, Barcelona, Spain, 08916
- Recruiting
- ICO Badalona - Hospital Universitari Germans Trias i Pujol,Servicio de Oncologia Medica
-
Contact:
- Teresa Moran Bueno
-
-
Navarra
-
Pamplona, Navarra, Spain, 31008
- Recruiting
- Clinica Universidad de Navarra, Servicio de Oncologia
-
Contact:
- Miguel Fernandez de Sanmamed Gutierrez
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patient has provided informed consent form (ICF).
- Males or females aged ≥ 18 years.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0~1.
- Life expectancy > 3 months judged by the investigator.
- Have histologically or cytologically confirmed advanced KRAS G12C-mutated NSCLC.
- Have at least one measurable lesion per RECIST 1.1.
- Have sufficient organ functions.
- With toxicities left from prior anti-tumor therapy resolved to baseline or CTCAE Grade 1 (neurotoxicity or alopecia ≤ Grade 2).
- Women of childbearing potential (WOCBP) and male patients with WOCBP partners must agree to use effective contraception method during the study specified period.
Exclusion Criteria:
- With clinically significant cardiovascular diseases.
- With active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- With clinically significant gastrointestinal diseases.
- With active infections.
- With uncontrollable or symptomatic pleural effusion, ascites, or pericardial effusion.
- With uncontrolled systemic diseases, such as hypertension or diabetes.
- Prior treatment with an inhibitor specific to KRAS G12C.
- Major surgery within 4 weeks prior to initiation of study treatment.
- With known allergies to the study drugs or components.
- Pregnant or lactating females, or female patients intend to become pregnant during participation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: GFH925+Cetuximab
|
GFH925 tablets administered orally daily.
Cetuximab administered intravenously Q2W.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase Ib: adverse events
Time Frame: 28 days
|
defined as number of patients with treatment emergent AEs
|
28 days
|
Phase II: objective response rate
Time Frame: up to 1 year after last patient in
|
defined as the percent of patients documented a PR/CR
|
up to 1 year after last patient in
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 25, 2023
Primary Completion (Estimated)
March 1, 2025
Study Completion (Estimated)
August 1, 2025
Study Registration Dates
First Submitted
February 12, 2023
First Submitted That Met QC Criteria
February 23, 2023
First Posted (Actual)
March 6, 2023
Study Record Updates
Last Update Posted (Actual)
March 12, 2024
Last Update Submitted That Met QC Criteria
March 7, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GFH925X0201
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advance Non-small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
-
Stanford UniversityAstraZenecaRecruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
Clinical Trials on GFH925
-
Innovent Biologics (Suzhou) Co. Ltd.Recruiting
-
Innovent Biologics (Suzhou) Co. Ltd.Recruiting
-
Innovent Biologics (Suzhou) Co. Ltd.RecruitingAdvanced Non-Small Cell Lung CancerChina